ANAESTHESIOLOGISTS AND PHARMACOLOGISTS have for many years been searching for an ideal local anaesthetic solution with prolonged action and low toxicity. Until now the only satisfactory way of prolonging the action of a local anaesthetic agent has been the addition of a vascoconstrictor such as epinephrine to the solutions. In spite of its inconvenience, this method is still in use. Oily solutions and anaesthetic suspensions have now been discarded because of the accidents which have occurred with them.
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OBJECTIVES OF THE StuDY
The basic objectives of the present study were: (1) to find a substance which could prolong the period of anaesthesia to a degree at least equivalent to the prolongation achieved with epinephrine; (2) to prepare an oil-free solution with sufIicient viscosity to permit slow absorption, one which was devoid of toxicity and tissue irritation and would conserve a reversible effect, would prolong analgesia, and would make possible the safe use of high concentrations.
These objectives appeared to us mandatory following our experiences with the use of the classical aqueous solutions which, in our hands, could sometimes produce unforeseen systemic reactions secondary to rapid absorption or intravascular injection.
Following the work of Pellerat and associates in France, 1 of Smirnov and Starlinger ~ in Russia, and of Paton 3 and Loder 4 in England in 1965, we began a clinical study of the use of mepivacaine (Carbocaine) in Subtosan. A year later we replaced mepivacaine with pri/ocaine (Citanest~) because of its high anaesthetic potency, its low toxicity, its prolonged action, and its high miscibility. At the same time pure polyvinylpirrolidone (Plasdone C) replaced Subtosan.
Many combinations of prilocaine-Plasdone C were tested, out of which eight different solutions remained of interest. The proiect was called the C]?C ( Citanest Polymeric Combination) project, and the compounds were called Prolanest, this 9 being a general term used to indicate a prolonged anaesthetic compound.
Plasdone C is a stable hygroscopic powder with a molecular weight in the range of 20,000 to 80,000 (average 40,000), corresponding to a chain of 192 to 720 monomes units. With its capacity for binding water and absorbing physiological and non-physiological products, Plasdone C shows a resemblance to the proteins PAtLaxDIS & CA1VIOUClS; LABORATORY STUDy AND CLINICAL TRIALS wITH PI~OLANF_~T 233 of normal plasma. Although the structural formula indicates that it should be an undissociated, neutral product, the aqueous solution is slightly acid, with a pH of 4, but with no buffering action. A slight migration of one fraction of polyvinylpirrolidone to the anode is observed in electrophoretic experiments (thus negative ions, i.e. a slightly negative charge).
Plasdone C is a typical colloid of tremendous surface area with possibilities to adsorb other molecules. Strong Plasdone solutions have, of course, a high viscosity and a high pK (viscosity coefficient), according to the Fiken Tascher formula.
Chemists have suggested that the mixing of prflocaine with Plasdone could fold the hydrocarbon chain, or that there might be a coil of hydrocarbons with pyrrolidone rings projecting in all directions. Crosslinking is a possibility, and the CO2 groups may be engaged for coupling. The binding equilibrium and the interaction forces have been analysed.
After exhausting chemical analyses, it has been impossible to conclude that we have achieved a new pharmaceutical entity. Analyses do not reveal eomplexing between Plasdone C and prilocaine. It does not seem that prilocaine is tightly bound to the polymer, because ff it were, the LDso values would have been higher ( Table I) . 
OBJECTIVES AND RESULTS OF THE LABORATORY EXPERLMENTS
The laboratory experiments were done with the eight solutions (Table II) , with particular attention to solutions CPC 241, CPC 251, and CPC 261. The objectives of the research were to determine irritability, toxicity, duration of (1) The duration of action is manifest on the rat sciatic nerve block (Tables III and IV) . There is no manifest prolongation of action on the isolated nerve and with peridural anaesthesia in the cat. (2) The Plasdoneprilocaine combination appears to be non-toxic and non-irritant in that the amount of necrosis seems to be minimal. ( MT = mid-thigh, H = hip: prilocaine solutions were in 0.6% NaCI. *Solutions of CPC 241 and prilocaine 4% diluted by equal volumes of 0.9% NaCI. Prilocaine solution in 0.6% saline. 
PARADIS & CAMOUGIS; LABORATORY STUDY AND CLINICAL TRIALS WITH PROLANEST

CLINICAL STUDY
Following experiments on isolated nerve, on rat sciatic nerve, on the cornea, and on intradermal wheals in guinea pigs ( see Tables V and VI) , having obtained from the research laboratory sufficient proof that the mixtures are not injurious to tissue, we proceeded with clinical evaluation. We first began using the mixtures in peripheral nerve blocks, and later we used them for surgical procedures. Four hundred and forty-eight infiltrations were given to one hundred and seventy patients for therapeutic nerve blocks. Seventy-five other patients were given epidural caudal anaesthesia and brachial plexus analgesia for various surgical procedures.
The surgical patients fall into two categories; first the young and healthy persons from the armed forces, their ages ranging from seventeen to thirty years; second, patients of ripe age ranging from thirty to eighty-five years of age. Individual records were kept for each infiltration, including progressive clinical notes concerning the progress of the patient. For surgical patients, careful records were kept of the exact volume administered and of the concentration of the solutions used. The onset and the spread of anaesthesia were noted, but special attention was paid to the duration of action and the recovery time, charted in terms of movement and sensation. Notes were also kept with regard to the prolongation of the postoperative analgesic effect, which in many instances eliminated the use of narcotics.
Eight different combinations of solutions were used for either therapeutic nerve blocks or surgical anaesthesia. Early in our investigation, 3 per cent prilocaine was used in 3.5 per cent, 10 per cent, and 15 per cent Plasdone C for therapeutic nerve blocks. Later, 4, 6, and 8 per cent prilocaine solutions were used in 8 per cent Plasdone C. For surgical anaesthesia, 3 and 4 per cent prflocaine in 3.5 and 8 per cent Plasdone C were used. After a few months carbonated solutions were evaluated. Epinephrine was never used in the study.
A special study was made regarding the formation of methaemoglobin. Fifty samples from ten patients were taken and analysed two, four, six, eight, and twelve hours following the administration of Prolanest, where a minimum of 600 mg. and a maximum of 1200 rag. of prilocaine-Plasdone had been injected. One patient received as much as 1100 mg. per day for seven days.
RESULTS WITH THEItAPEOnC NERVE BLOCKS
For therapeutic nerve blocks (Table VII) , results classified as excellent correspond to patients who were free of symptoms after the first infiltration and did not necessitate more than two further infiltrations. Results classified as good correspond to those who were partially relieved of their symptoms and who were kept under treatment for many months. Results classified as nil correspond to those who showed no improvement after two or three infiltrations. In surgery, seventy-five patients were operated upon under regional anaesthesia with Prolanest. Table VIII indicates the type of solution used and the regional anaesthesia performed. Tables VIII, IX , and X give, at a quick glance, a record of the classification of patients by age, the doses of Prolanest used, the onset of action, and the duration of action. Comparative studies were made in Table XI.  Table XII gives the comparative evaluation between the type of solution used and the necessity of postoperative sedative, within five hours following the operation.
It has been noted that narcotics were seldom necessary when CPC 241 was used and especially with caudal anaesthesia and brachial block. This appears to be due to the fact that, on one hand, the viscosity of this solution is greater than that of CPC 61 and the usual prilocaine solutions, and, on the other, Plasdone permits the use of higher concentrations of prilocaine (4g) without endangering the nerve fibre. The side-effects taken into consideration in the study are the usual complications encountered with all regional anaesthesia. They were noted and tabulated during the time of the anaesthetic procedure and up to five hours postoperatively. Table XIII gives an account of the type and the frequency of these side-effects compared with the type of solution used. It is noteworthy that the best results were obtained from solution CPC 241. In terms of the objectives of the present study, we have attained positive results consistently, both in the laboratory and in clinical investigation.
The laboratory experiments clearly demonstrated, for all solutions tested: (1) lack of irritability to the tissues; (2) complete reversibility of action; (3) a tolerance at least equal to that obtained with priloeaine in aqueous solution; (4) a prolongation of action with mixture CPC 241 and CPC 251 on the sciatic nerve block.
The clinical investigation showed: (1) that the duration of action is notably superior to that found in laboratory experimentation; (2) that the duration of action of Prolanest is superior to corresponding concentrations of prilocaine with epinephrine; (3) that tolerance by the tissues is strikingly evident; (4) that the action of all solutions, even with as high a concentration as 8 per cent prfloeaine in 8 per cent Plasdone, is totally reversible; (5) that the solutions, being isotonic, do not cause dehydration of the nerve tissues; (6) a very beneficial result in surgery, in that Prolanest, especially CPC 241, prolongs the postoperative analgesic effect; this was particularly noted with brachial blocks and caudal analgesia (it is to be noted that no systemic reactions ever developed, as is so frequently the case with aqueous solutions ); (7) that methaemoglobin does not develop with doses as high as 1200 mg. We postulate that the absence of methaemoglobin formation is due to the fact that the absorption of priloeaine is considerably slowed, or that the Plasdone C possesses a reducing action on methaemoglobin.
CONCLUSION
Prolanest is a new solution of prilocaine with long action. This solution is well tolerated, non-irritant, totally reversible, and free of side-effects, and it causes no methaemoglobin formation. We believe it is an improvement for therapeutic nerve block, for surgery of the extremities, and for saddle blocks. We have found its use safer with elderly patients, owing to its slow absorption and minimal side-effects. R~su~ L'addition d'~pin6phrine a 6t6 et est encore le seul moyen de prolonger raetion d'un anesth6sique local. Bas6 sur les exp6riences des ehercheurs frangais, allemands, russes et am6ricains, lesquels ont exp6riment6, vers les ann6es 1948, rusage de la procaine dilu6e dans la polyvinylpirrolidone, nous avons rechereh~ la formation d'un anesth6sique ~ action prolong6e, non plus par l'addition d'6pin6phrine, mais par l'association de l'agent anesth6sique hun solvent qui retarde l'absorption du produit, permet son contact plus prolong6 avec le nerf.
Nous avons fait pr6parer des solutions diverses de polyvinylpirrolidone avec de la prilocaine. Nous avons port6 notre attention vers la prilocaine, parce que cet agent anesth6sique est le moins toxique et le plus rapide d'action, qu'il a une action plus prolong~e que celle de tousles autres anesth6siques. Mais la principale raison, est l'extraordinaire facilit6 avec laquelle la prilocaine se m~lange avec ]a polyvinylpirrolidone. Cette miscibilit6 a fait penser aux chimistes et aux pharmacologistes, que ce m~lange &ait plus qu'un simple m~lange physique, plus qu'une simple solution, que c'6tait peut-~tre la r~alisation d'un complexe nouveau par "binding".
L'objection principale ~t l'usage de la prilocaine, c'est la formation de m~th6mo-globine. Ce point de vue a 6t6 tout sp~cialement 6tudi~ durant ]a recherche fate. Les experiences de laboratoire ont port6 sur la r~action du m61ange sur les nerfs sciatiques isol~s, sur la com~e, au cours des p~ridurales sur le chat ou ~ celle de l'irritabilit~ du nouveau compos6, sa toxicitY, sa tol6rance et sa r6versibilit& L'6tude clinique a envisag~ d'abord les indications th6rapeutiques au cours des infiltrations. Puis cette 6tude s'est ~largie au domaine de la chirurgie, vu les bons r~sultats obtenus avec les infiltrations.
L'on a prouv$ au laboratoire, la s~curit6 de ce m61ange nouveau ou de ce complexe nouveau. En clinique, nous avons 6tudi6 le complexe en toute s~curit6 de toxicit6, convaincu que la tolerance de la prilocaine ~tait augment~e et que sa toxicit6 en Stait par le fait, diminu6e. Les r6sultats ont prouv~ que l'augmentation de la dur$e &ait plus longue que celle pr~vue, sp6cialement avec une proportion qui a retenu entre autre notre attention, soit la solution CPC 241, i.e. celle contenant 4 pour cent de prilocaine et 8 pour cent de polyvinyl. Mais le plus ~vident est la grande tolerance au produit, la faible toxicit6, la propri6t6 analg~-sique post-op~ratoire et l'absence totale de m~th~moglobine.
En pratique, nous ne voudrions pas revenir aux solutions aqueuses, vule danger tr~s grand de r~actions syst~miques lors de doses fortes, comme au cours de ranesthSsie caudale et du blocage du plexus brachial et des infiltrations du sympathique lombaire. L'absence de m6th6moglobine avec des doses aussi fortes que 1200 mg., ajoute du poids h notre preference de ce complexe sur le m~me produit, en solution aqueuse.
